Joel Fuhrman MD has cured hundreds of people of diabetes using diet and lifestyle. The American Diabetic Association wanted him to write about his work — but then objected because their sponsor, Eli Lilly drug company, might feel threatened by an MD promoting a cure which could destroy the market for their diabetes medications. This is an excerpt from Dr. Furhman’s presentation at the Healthy Lifestyle Expo 2007. To learn more, or to get a copy of Dr. Fuhrman’s full talk on DVD, go to: secure.vegsource.com

Agency For Healthcare Research And Quality News And Numbers: High Cholesterol, Diabetes Lead Drug Spending For The …
Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 – about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers. Metabolic drugs, which are used to lower cholesterol levels, keep diabetes under control and for weight and thyroid problems, topped …

Read more on Medical News Today

Probe: Diabetes drug maker kept risks quiet
New York, N.Y. — A Senate report said Saturday that drug maker Glaxo-SmithKline knew of possible heart attack risks tied to Avandia, its diabetes drug, years before such evidence became public.

Read more on The Des Moines Register

When people discuss the ever-rising costs of health care, one of the most common complaints is the sometimes exorbitant price of prescription medicines. For those with multiple medical conditions or the elderly, the costs can become so overwhelming that overseas options are sought or, worst case, patients refrain from necessary treatments in order to pay for other life necessities.

In a long-term effort to reduce health care costs for Americans in the most need of such assistance, President Obama took another step in the process of reform by announcing an $80 billion deal with pharmaceutical companies to reduce prescription drug costs.

While the details of the plan were vague, it was noted that the $80 billion savings would occur over the course of the next decade and primarily come at the hands of drug manufacturers to try to help those who fall into the category of Medicare prescription drug coverage that leaves many customers with high costs.

Speculation began immediately after the announcement, as both sides of the Congressional aisle and the health care reform issue expressed concerns about the plan. Some believe the $80 billion cut will hurt drug companies, but others argue that drug companies will ultimately manufacture alternatives and benefit from the distribution of higher quantities of cheaper medications.